Core Viewpoint - The company has experienced steady growth in its pharmaceutical business in recent years, driven by a focus on a major client strategy and a CDMO business model [1] Group 1: Business Strategy - The company has established partnerships with several leading global pharmaceutical enterprises and is actively expanding its client base to include strategic and high-viscosity clients [1] - The pharmaceutical division has formed stable commercial relationships with a number of high-quality domestic and international clients, with an expanding scope and depth of cooperation [1] Group 2: Product Pipeline and Future Growth - The company aligns its product pipeline with the business lines of its clients, primarily focusing on products under patent protection, which is expected to drive long-term growth in the pharmaceutical business as these products are promoted [1] - Future growth will focus on expanding mature businesses, including small molecule CDMO, starting materials, registered raw materials, GMP intermediates, and active pharmaceutical ingredients (APIs) [1] - The company aims to capture new projects from existing clients in small molecules and small nucleic acid CDMO, as well as new projects from new clients [1] - Significant investments will be made in emerging business development, including CDMO for peptide products, radiopharmaceuticals, animal health CDMO, generic drug intermediates, APIs, and cosmetic raw materials [1]

Group 1: Company Overview - Company held a specific investor meeting on January 5, 2026, in Shanghai, attended by nine institutions including Tianfeng Securities and Southern Fund [1][2] - Senior Vice President and Secretary of the Board, Chen Feibiao, along with Securities Affairs Representative Dai Yiyi, discussed key issues such as the progress in the new energy business, overseas base layout, and pharmaceutical business planning [1][2] Group 2: New Energy Business - The new energy business is focused on the sales of LiFSI and electrolyte products, with a breakthrough in revenue achieved in 2025 and expected continued growth in 2026 [2] - The lithium hexafluorophosphate project is currently in the technical improvement stage, with ongoing optimization of product competitiveness through systematic process development [2] - The company leverages its long-standing experience in chemical synthesis to enhance its market position in the new energy sector [2] Group 3: Overseas Operations - The UK production base is operating smoothly in 2026, while the Malaysian base is under phased construction, primarily aimed at producing agricultural CDMO products [3] - The company plans to integrate resources from China, the UK, and Malaysia to provide comprehensive supply chain solutions covering the entire product lifecycle [3] Group 4: Pharmaceutical Business - The pharmaceutical business focuses on a CDMO model and has established partnerships with several leading global pharmaceutical companies, while also expanding its client base [4] - The business primarily serves products under patent, with long-term growth expected as these products are promoted [4] - Future development will emphasize small molecule CDMO, starting materials, and registration materials, while also investing in emerging areas such as peptides and radiopharmaceuticals [4] Group 5: Risk Management - The company acknowledges potential revenue impacts from the expiration of patents for agricultural clients but plans to mitigate this through product and technology upgrades [6]

Core Viewpoint - Company focuses on enhancing its core businesses in agricultural protection and pharmaceutical CDMO through overseas base expansion and R&D innovation, while steadily advancing its new energy business for long-term development [2] Group 1: Investor Relations Activity - On December 19, the company held an investor relations activity with five institutions, including Guohai Securities and Nomura Asset Management, discussing key issues such as agricultural protection business layout, pharmaceutical CDMO development, R&D innovation direction, and capital operation plans [1] - The meeting was attended by the company's Senior Vice President and Secretary of the Board, Chen Feibiao, and Securities Affairs Representative Dai Yiyi [1] Group 2: Agricultural Protection Business - The company plans to enhance its overseas base layout, establishing Malaysia as a second overseas base for a differentiated supply chain, collaborating with production bases in China and the UK [1] - The agricultural protection industry is highly concentrated, and the company has formed long-term strategic partnerships with several international agrochemical companies, covering all stages of the product lifecycle [1] Group 3: Pharmaceutical Business - The pharmaceutical business is expanding its coverage and deepening cooperation, focusing on products under patent protection [1] - The company aims for steady long-term growth by enhancing technical capabilities to strengthen customer cooperation [1] Group 4: R&D Innovation - The company is expanding into emerging fields such as peptide and radioactive drugs, while continuing to develop small molecule CDMO and starting materials [1] - The team has experience in delivering peptide and PEG linker products, optimizing synthesis routes based on customer needs [1] Group 5: CDMO Core Competitiveness - The company's core competitiveness lies in strong technological innovation, high safety and environmental standards, efficient production management, and a strict quality assurance system [1] - These advantages have earned recognition from leading global agricultural and pharmaceutical companies, ensuring stable and long-term cooperation [1] Group 6: Capital Operation - Currently, the company has no plans for secondary market financing, focusing capital expenditures on the construction of coastal and Malaysian bases [1] - As of the first three quarters of 2025, the company reported a net cash flow from operating activities of approximately 900 million yuan, sufficient to support planned capital expenditures [1] Group 7: New Energy Business - The company primarily sells LiFSI and electrolyte products, while improving the technology for lithium hexafluorophosphate [1] - It is expected that the new energy business will achieve significant revenue breakthroughs in 2025, leveraging its R&D and production advantages in fine chemicals [1]

Group 1: Agricultural Protection Business - The agricultural protection business currently accounts for a significant portion of the company's revenue, with plans for future development focusing on maintaining steady growth in this concentrated industry [1] - The company has established long-term strategic partnerships with multiple international agricultural companies, covering all stages of the product lifecycle [1] - The company has production bases across China and an overseas base in the UK, with plans to establish Malaysia as a second overseas base to enhance supply chain differentiation [1] Group 2: Pharmaceutical Business Development - The pharmaceutical business is rapidly developing, with a focus on attracting new strategic and high-viscosity clients [2] - The company has formed stable commercial relationships with several high-quality domestic and international clients, expanding its business cooperation scope [2] - Future growth in the pharmaceutical sector is expected as the company continues to promote products under patent protection and enhance its technical capabilities [2] Group 3: Research and Development Directions - The company is expanding its R&D efforts from traditional small molecule drugs to include amino acids, peptides, and other advanced drug delivery systems [3] - The team is focused on accelerating the transition of early clinical projects for clients, providing diverse linker synthesis services for ADC/PROTAC drugs [3] - These new directions are anticipated to broaden the company's CDMO service offerings and enable the acquisition of more projects [3] Group 4: CDMO Capabilities and Client Relationships - The company emphasizes enhancing its technical innovation, safety standards, production management, and quality assurance systems to meet client needs [4] - A strong intellectual property confidentiality system and a commitment to integrity have earned the company recognition from leading global agricultural and pharmaceutical clients [4] - The selection of suppliers by international clients is based on comprehensive evaluations of technology, regulations, environmental standards, and quality, leading to stable and long-term partnerships [5] Group 5: Capital Operations and Financial Outlook - Currently, the company has no plans for capital operations focused on secondary market financing, with recent capital expenditures directed towards the construction of coastal and Malaysian bases [5] - The net cash flow from operating activities for the first three quarters of 2025 was approximately 9 billion, sufficient to support planned capital expenditures [5] - Future financing plans will be evaluated based on strategic investment needs and market conditions [5] Group 6: New Energy Business - The company primarily focuses on the sales of lithium hexafluorophosphate and electrolyte products, with ongoing technical improvements in the lithium hexafluorophosphate project [5] - Revenue from the new energy business is expected to break through in 2025, with plans to deepen market penetration and optimize the supply chain [5]

Core Viewpoint - The company, Lianhua Technology, aims to expand its mature business segments while investing in emerging areas, particularly in the CDMO (Contract Development and Manufacturing Organization) sector for small molecules and nucleic acids [1] Group 1: Business Expansion - The company plans to continue growing its mature businesses, including small molecule CDMO, starting materials, registered materials, GMP intermediates, and advanced raw materials [1] - It aims to capture new projects from existing clients and attract new clients in the small molecule and small nucleic acid CDMO sectors [1] Group 2: Investment in Emerging Areas - The company is heavily investing in the development of emerging businesses, including peptide CDMO, radiopharmaceutical-related CDMO, animal health CDMO, generic drug intermediates, APIs, and cosmetic raw materials [1] - This year, the company has focused on technological R&D in pharmaceutical products, expanding from traditional small molecules to amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [1] Group 3: Service Capabilities - The team is enhancing client support for early clinical project transitions by providing diverse linker synthesis services required for ADC/PROTAC drug development [1] - The company has experience in delivering linker types from gram to hundred-gram levels and can design and optimize linker structures and synthesis routes based on client needs [1] - These new initiatives are expected to broaden the company's pharmaceutical CDMO service offerings and enable it to undertake more projects [1]

Core Insights - The company has shown significant recovery in net profit during the first three quarters of 2025, with a revenue of 4.72 billion yuan, representing an 8.25% year-on-year increase, and a non-recurring net profit of 300 million yuan, up 1504% year-on-year [1] - The company is expanding its mature pharmaceutical business while investing heavily in new development directions, including advancements in drug technology and services [2] - The agricultural protection market is beginning to recover, with the company establishing a global supply chain through its Malaysian base, which is expected to start production within 1 to 2 years [3] - The company is also investing in new energy products, with significant projects underway to enhance its production capacity in lithium-related products [3] Summary by Sections Financial Performance - In the first three quarters of 2025, the company achieved an operating income of 4.72 billion yuan, a year-on-year increase of 8.25% - The non-recurring net profit reached 300 million yuan, reflecting a substantial year-on-year growth of 1504% - The gross profit margin stood at 25.96%, an increase of 3.25 percentage points compared to the previous year [1] Pharmaceutical Business Development - The company is focusing on expanding its pharmaceutical product technology research and development, moving from traditional small molecule drugs to amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [2] - The team is enhancing early clinical project conversion for clients by providing diverse linker synthesis services necessary for developing ADC/PROTAC drugs [2] Agricultural Protection Market - The agricultural protection market is recovering from a period of excess inventory due to global supply chain disruptions from 2019 to 2022, with demand expected to rebound in the second half of 2024 [3] - The company is collaborating with multiple international agricultural/plant protection companies to drive CDMO business through technological innovation [3] - The Malaysian base is under construction and aims to support CDMO business for agricultural protection products during the patent period, with production expected to start in 1 to 2 years [3] New Energy Initiatives - The company is investing 650 million yuan in projects to produce 200,000 tons of electrolyte, 20,000 tons of LT612 (lithium hydroxide monohydrate), and other lithium-related products [3] - The planned production capacity for lithium hexafluorophosphate is set at 20,000 tons per year, while the capacity for lithium bis(fluorosulfonyl)imide is projected at 10,000 tons per year [3] - The new energy business has achieved revenue breakthroughs, primarily from sales of LiFSI and electrolyte products, while the lithium hexafluorophosphate project is still undergoing technical improvements [3]

Charles Zhuang 庄怀超 SFC CE: BTE209 微信: zhuangcharles; 电话: (852) 9748 7114; 28 Nov 2025 环球富盛理财有限公司 联化科技 Lianhe Chemical Technology (002250.SZ) 盈利能力修复，新能源板块打开未来成长空间 Profitability repair & New energy sector opens up future growth space 最新动态 ➢ 做大成熟医药业务，大力投入新方向的开发。2025 年以来，公司在医药产品技术研发方面持续发力，从传统小 分子药物拓展到氨基酸、多肽、PROTAC/ADC 连接子、寡核苷酸等。团队通过持续开发、加速赋能客户的早期 临床项目转化，为客户提供开发 ADC/PROTAC 药物所需的多样性 Linker 合成服务，并具备多肽，PEG 等类型 Linker 克级到百克级别的交付经验。同时，公司能够根据客户需求进行 Linker 的结构和合成路线的设计及优化。 这些新方向的尝试有望拓展公司医药 CDMO 业务的服务领域，帮助公司承接更多的项目。 ➢ 植保 ...

Group 1: Pharmaceutical Business Development - The company’s pharmaceutical business is rapidly developing, focusing on a major client strategy and CDMO business model, with partnerships established with several leading global pharmaceutical companies [1] - The pharmaceutical division has formed stable commercial relationships with a number of high-quality domestic and international clients, leading to an expansion of the business coverage and deepening cooperation [1] - Future growth in the pharmaceutical sector is anticipated as the company continues to promote products during clients' patent periods [1] Group 2: Research and Development Expansion - The company is expanding its R&D efforts into new areas, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials [2] - New directions in R&D include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides, with a focus on providing diverse linker synthesis services for ADC/PROTAC drug development [2] - These initiatives are expected to broaden the service scope of the pharmaceutical CDMO business and enable the company to undertake more projects [2] Group 3: Key Product Updates - The company continues to provide advanced intermediates K amine for chlorantraniliprole under a long-term partnership with a client, with a stable pricing model based on cost-plus [3] - The company adheres to a long-term contract strategy, ensuring trust and integrity in client relationships [3] Group 4: New Energy Sector Outlook - The company primarily sells LiFSI and electrolyte products, with ongoing technical improvements in lithium hexafluorophosphate projects [4] - Revenue from the new energy business is expected to break through in 2025, with a focus on large client strategies and enhancing production capabilities [4] Group 5: Agricultural Protection Business - The agricultural protection industry is highly concentrated, with the company engaging in CDMO business driven by technological innovation and establishing long-term strategic partnerships with multiple international agricultural companies [6] - The company has multiple production bases in China and overseas, including a new base in Malaysia to meet supply chain needs [6] - The company aims to provide differentiated, one-stop supply chain solutions leveraging its comprehensive chemical supply chain in China and flexible production policies in the UK and Malaysia [6]

Group 1: New Energy Business Development - The company has focused on chemical synthesis since its establishment and is now entering the new energy sector, leveraging its competitive commercialization capabilities [1] - Current products in the new energy business include electrolytes, with plans for customer communication, project development, and quality system construction [1] - The company aims to achieve a breakthrough in new energy business revenue in 2025, focusing on large customer strategies, enhancing production capabilities, and strengthening quality management [1] Group 2: Pharmaceutical Business Growth - The pharmaceutical business is rapidly developing, primarily through a CDMO model, with partnerships established with several leading global pharmaceutical companies [2] - The company is actively expanding its client base and focusing on strategic, high-viscosity customers, which is expected to drive future growth [2] Group 3: Malaysia Base Development - The product planning for the Malaysia base is centered on crop protection products, with positive feedback from clients regarding the overseas base construction [3] - The Malaysia base is currently in the construction phase, primarily intended for the production of patented crop protection products [3] Group 4: Impact of Tariff Changes - Tariff policies have a limited impact on the company's overall operations, as the export business to the U.S. constitutes a small portion of total operations [4] - The company maintains proactive communication with clients regarding supply chain stability and tax optimization in response to tariff changes [4] Group 5: Capital Expenditure and Funding - Current capital expenditures are focused on the coastal and Malaysia bases, with a net cash flow from operating activities of approximately 900 million yuan in the first three quarters of 2025 [5] - The company aims to gradually reduce its debt-to-asset ratio to lower operational risks and ensure stable operations [5] Group 6: K Amine Product Update - The company continues to provide the advanced intermediate K Amine for chlorantraniliprole under a CDMO model, maintaining a long-term partnership with the client [6] - A long-term framework agreement has been signed for related advanced intermediates, with a pricing model based on cost-plus for stable processing fees [6]

Core Viewpoint - The company has reported strong financial performance in Q3 2025, with significant year-on-year growth in both revenue and net profit, indicating a positive outlook for its business segments [1]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 4.718 billion yuan, representing a year-on-year increase of 8.25%. The net profit attributable to shareholders was 316 million yuan, up 871.78% year-on-year, while the non-recurring net profit reached 300 million yuan, reflecting a year-on-year increase of 1504.77% [1]. - In Q3 2025, the company reported a revenue of 1.569 billion yuan, which is a quarter-on-quarter decrease of 4.34%. The net profit attributable to shareholders was 92 million yuan, down 47.26% quarter-on-quarter, and the non-recurring net profit was 91 million yuan, down 43.06% quarter-on-quarter [1]. Development Trends - The price of lithium hexafluorophosphate has increased significantly, from 49,300 yuan per ton in July to 99,000 yuan per ton by October 27. Similarly, the price of lithium bis(fluorosulfonyl)imide (LIFSI) rose from 67,500 yuan per ton in mid-September to 72,000 yuan per ton [2]. - The company has a planned production capacity of 20,000 tons per year for lithium hexafluorophosphate and 10,000 tons per year for LIFSI. The previous low prices had limited the company's production capacity in the new energy chemical business, but the recent price increases are expected to improve profitability [2]. Industry Outlook - The agricultural and pharmaceutical sectors are expected to continue their upward trend. The company's major client, FMC, has consistently exceeded earnings expectations, and the agricultural chemical market is entering a new growth cycle as inventory levels normalize [3]. - The company has acquired a 20% stake in its subsidiary, JunTai Pharmaceutical, for 25 million yuan, which has a production capacity of 100 tons for a key intermediate in pharmaceuticals. The ongoing development of the company's pharmaceutical CDMO business is anticipated to yield positive results [3]. Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 500 million yuan and 620 million yuan, respectively. The current stock price corresponds to a P/E ratio of 22.2x for 2025 and 17.8x for 2026 [4]. - The target price is set at 14.0 yuan, maintaining an "outperform industry" rating, which corresponds to a P/E ratio of 25.6x for 2025 and 20.5x for 2026, indicating a potential upside of 15.5% from the current stock price [4].